{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.1","upperLimit":"139.9","value":"76.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the time from first dose until death due to any cause. Censoring was performed using the date of last known contact for those who were alive at the time of analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG000","title":"High Grade (WHO G3/G4) Glioma (HGG)"}],"paramType":"MEDIAN","populationDescription":"ITT/Evaluable population - Primary and expansion cohort combined.","reportingStatus":"POSTED","timeFrame":"From study treatment start date until date of death from any cause, assessed up to 92 months (cut-off date for end of study = 10-Dec-21)","title":"Overall Survival (OS) in the High Grade (WHO G3/G4) Glioma (HGG) Cohort","type":"SECONDARY","unitOfMeasure":"Weeks"}